Industry news that matters to you.  Learn more

BrainCare, a New Computerized Testing Solution from NeuroTrax, Promotes Brain Wellness After Stroke and Traumatic Brain Injury

NeuroTrax, a pioneer and leader in the emerging brain wellness industry, recently announced the global availability of BrainCare™, a cognitive assessment and report solution to aid clinicians in advancing brain wellness of stroke survivors and traumatic brain injury (TBI) patients.

Aethlon Medical and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target

Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), recently announced that researchers have isolated brain-derived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.

Aethlon Medical and Exosome Sciences Announce Brain Research Discoveries

Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), recently announced that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.

KineMed Announces Agreement with Amgen to Develop Kinetic Biomarkers of Brain Proteinopathies

KineMed, Inc. (www.kinemed.com) recently announced an agreement with Amgen to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases.

UC Davis Study Finds Biomarker Differentiating the Inattentive and Combined Subtypes of ADHD

Using a common test of brain functioning, UC Davis researchers have found differences in the brains of adolescents with the inattentive and combined subtypes of attention-deficit/hyperactivity disorder (ADHD) and teens who do not have the condition, suggesting that the test may offer a potential biomarker for differentiating the types of the disorder.